Abstracts

Citation

D Burger, E Acosta, N van Ewijk, C Taylor, P Bollen, T Ruane, A Colbers, A Turkova, R Di Francesco, G Morse, R Browne. PROFICIENCY TESTING SUPPORTS COMBINED ANALYSIS OF DOLUTEGRAVIR PHARMACOKINETIC DATA. Presented at: CROI 2019.

Citation

T Ruel, E Acosta, RP Singh, C Alvero, K George, S Popson, C Vavro, R Hazra, A Wiznia. Dolutegravir pharmacokinetics, safety and efficacy in HIV+ children 2 to 6 years old. Presented at: CROI 2017; 2017 Feb 16.

Citation

CL Boyce, RA Smith, R Nixon, MD Bishop, SM Styrchak, K Knowles, S Brummel, TD Ruel, A Wiznia, S Lockman, L Chinula, PK Drain, GS Gottlieb, LM Frenkel. Genotypic and Phenotypic Dolutegravir Resistance in Pregnant Women and Children Living with HIV-1. Presented at: International Workshop on HIV Drug Resistance and Treatment Strategies; 2023 Sep 20.

Citation

Hardik Chandasana, Kristina Brooks, Ann M. Buchanan, Lionel Tan, Anna Turkova, Angela Colbers, Judy Hopking, Marika Ciuffa, Michael McKenna, Andrew Wiznia, Sean Brummel, Adrie Bekker, Tim Cressey, Helena Rabie. A Single Once Daily ABC/DTG/3TC Tablet Predicts Safe and Effective Exposures in Children 3 to 6 kg. Presented at: CROI 2024; 2024 Mar 05.